BJE6-106

Research use only, not for human use.

BJE6-106 (B106)?is a potent, selective PKCδ inhibitor with IC50 of 50 nM, displays excellent selectivity over classical PKC isozymes.

BJE6-106 (B106)?is a potent, selective PKCδ inhibitor with IC50 of 50 nM, displays excellent selectivity over classical PKC isozymes (a 1,000-fold PKCδ selectivity over PKCα); induces cell growth inhibition in melanoma cell lines with NRAS mutations at nanomolar concentrations; induces phosphorylation (activation) of JNK1/2 (T183/Y185) most strongly after two hr of exposure in SBcl2 cells, induces phosphorylation of MKK4, JNK and H2AX in NRAS mutant melanoma WM1366 cells.

BJE6-106 (B106) (0.2 μM, 0.5 μM;24-72 hours) suppresses cell survival in melanoma cell lines with NRAS mutations.BJE6-106 (B106) (0.2 μM, 0.5 μM;6-24 hours) triggers caspase-dependent apoptosis, increases the activity of caspase 3/7, the effect of B106 is greater than rottlerin (10-fold) in SBcl2 cells.BJE6-106 (B106) (0.5 μM;2-10 hours) activates the MKK4-JNK-H2AX Pathway by inducing MKK4, JNK and H2AX activation at different times in SBcl2 cells. Cell Viability Assay Cell Line:Melanoma cell lines with NRAS mutations: SBcl2, FM6, SKMEL2, WM1366, WM1361A, and WM852 cells Concentration:0.2 μM, 0.5 μM Incubation Time:24 hours, 48 hours, or 72 hours Result:Inhibited cell survival in melanoma cell lines.Apoptosis Analysis Cell Line:SBcl2 cells Concentration:0.2 μM, 0.5 μM Incubation Time:6 hours, 12 hours, or 24 hours Result:Induced caspase 3/7 activation.Western Blot Analysis Cell Line:SBcl2 cells Concentration:0.2 μM, 0.5 μM Incubation Time:2 hours, 5 hours, 10 hoursResult:Increasedphosphorylation of MKK4, JNK and H2AX.

——

B106

Angiogenesis

PKC

PKC

——

——

1564249-38-2

381.475

C26H23NO2

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (131.07 mM)

O=CC1=C2C(C=CC(C)(C)O2)=CC(CCN3C4=C(C5=C3C=CC=C5)C=CC=C4)=C1

6-(2-(9H-carbazol-9-yl)ethyl)-2,2-dimethyl-2H-chromene-8-carbaldehyde

(-20℃)

With Ice Pack

≥ 2 years